With Noom, you can expect sustainable weight-loss results by developing healthier eating habits, increasing your physical activity, and changing your relationship with food. 98% of Noomers say Noom helps change their habits and behaviors for good.

Noom Med gives you access to a qualified clinician who can prescribe weight-loss medications like Ozempic, Wegovy, and Zepbound if it is deemed appropriate for your treatment plan based on the clinician evaluation.

Noom provides instant access to AI and human-led coaching via chat to all users. Our coaches, many of whom are board-certified health professionals, are expertly trained in the Noom method. They offer personalized guidance, answer your questions, and help you stay on track with your goals.

Noom can be suitable for people with medical conditions. The programs can be customized to fit many of them as well as various dietary needs. However, Noom is not for everyone. You cannot use the service if you are under 18 years old, pregnant, have an eating disorder, or if you are underweight (according to the Center for Disease Control and Prevention, a BMI falling below 18.5 is considered to be underweight).

Noom GLP-1^Rx Program is our new, affordable weight-loss program that pairs high-quality medications with powerful lifestyle change to help you achieve sustainable weight loss that lasts. Our program is backed by Noom’s expertise in psychology and science. If you qualify, it is shipped to your door in 7 days.*

*Not all medications are available for home delivery. Availability of home delivery will depend on your insurance or cash pay status. If your clinician feels compounded medications are clinically appropriate for you, any compounded medications are not approved by the FDA or reviewed for quality, safety or efficacy. Novo Nordisk, Inc. is the only United States company with FDA-approved products containing semaglutide, identified under the trade names Rybelsus^®, Ozempic^® and Wegovy^®. Lilly USA LLC is the only United States company with FDA-approved products containing tirzepatide identified under the trade names Zepbound^® and Mounjaro^®